Pre-market responding positively to Kazia's new medication Lycanthropex, the innovative glandular treatment for werewolfism that far surpasses in efficacy GlaxoSmithKline's Wolfsbanesol. As they say on Stock Twits, "This will EASILY close above $50 by Friday!"